Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Multiple Myeloma Progression: Dependence on Bone Marrow Adipose Tissue

Michaela Reagan, PhD, Carolyne Falank, PhD, Heather Fairfield, MS, Michelle McDonald, PhD, Peter Croucher, BSc, PhD, Clifford J. Rosen, MD

Blood (2016) 128 (22): 3262.

https://doi.org/10.1182/blood.V128.22.3262.3262

Published: 2016

Journal Articles

Anti-Sclerostin Treatment Prevents Multiple Myeloma Induced Bone Loss and Reduces Tumor Burden

Michaela R. Reagan, PhD, Michelle McDonald, PhD, Rachael Terry, PhD, Jessica Pettitt, Lawrence Le, Sindhu Mohanty, PhD, Michaela Kneissel, PhD, Ina Kramer, PhD, Daniel Brooks, Mary Bouxsein, PhD, Clifford J. Rosen, MD, Irene M. Ghobrial, MD, Peter Croucher, BSc, PhD

Blood (2015) 126 (23): 119.

https://doi.org/10.1182/blood.V126.23.119.119

Published: 2015

Journal Articles

The Effect of Myeloma Cells on Bone Homeostasis Is Heterogenous and Correlates with Underlying Genetic Lesions and Bone Disease In Vivo

Deepika Kassen, BSc, MSc, PhD, Neil Rabin, FRCPath, Darren Lath, Peter Croucher, BSc, PhD, Kwee Yong, MA, (Oxon), PhD, FRCP, FRCPath

Blood (2010) 116 (21): 4052.

https://doi.org/10.1182/blood.V116.21.4052.4052

Published: 2010

Journal Articles

Targeting CDK4/CDK6 Impairs Osteoclast Progenitor Pool Expansion and Blocks Osteolytic Lesion Development in Multiple Myeloma.

Rentian Feng, PhD, Xiangao Huang, PhD, Les Coulton, PhD, Hendrik De Raeve, MD, Maurizio DiLiberto, PhD, Scott Ely, MD, MPH, Guozhi Xiao, PhD, Min Luo, MD, Eline Menu, PhD, Peter Croucher, MD, G. David Roodman, MD, PhD, Karin Vanderkerken, MD, Selina Chen-Kiang, PhD, Suzanne Lentzsch, MD, PhD

Blood (2009) 114 (22): 298.

https://doi.org/10.1182/blood.V114.22.298.298

Published: 2009

Journal Articles

In Vivo Evaluation of a BAFF Inhibitor AMG 523 Suggests Lack of Efficacy in Multiple Myeloma Tumor Models.

Jiangchun Xu, MD, PhD, Evy D. Leenheer, Ph.D., Julia Piasecki, MS, Anne-Renee V. De Vries, Ph.D., Karin Vanderkerken, Ph.D., Peter Croucher, Ph.D.

Blood (2007) 110 (11): 1518.

https://doi.org/10.1182/blood.V110.11.1518.1518

Published: 2007

Journal Articles

Myeloma bone disease and proteasome inhibition therapies

Evangelos Terpos, Orhan Sezer, Peter Croucher, Meletios-Athanassios Dimopoulos

Blood (2007) 110 (4): 1098–1104.

https://doi.org/10.1182/blood-2007-03-067710

Published: 2007

Journal Articles

Inhibition of p38α MAPK Reduces Tumor Burden, Prevents the Development of Myeloma Bone Disease, and Increases Survival in the 5T2 and 5T33 Murine Models of Myeloma.

Karin Vanderkerken, PhD, Satya Medicherla, PhD, Les Coulton, PhD, Benjamin Van Camp, MD, PhD, Andy Protter, PhD, Linda Higgins, PhD, Eline Menu, PhD, Peter Croucher, PhD

Blood (2006) 108 (11): 3436.

https://doi.org/10.1182/blood.V108.11.3436.3436

Published: 2006

Journal Articles

The Combination of Bortezomib, Melphalan, Dexamethasone and Intermittent Thalidomide (VMDT) Is an Effective Regimen for Relapsed/Refractory Myeloma and Reduces Serum Levels of Dickkopf-1, RANKL, MIP-1α and Angiogenic Cytokines.

Evangelos Terpos, Athanasios Anagnostopoulos, Deborah Heath, Efstathios Kastritis, Dimitrios Christoulas, Nikolaos Anagnostopoulos, Maria Roussou, Konstantinos Tsionos, Peter Croucher, Meletios A. Dimopoulos

Blood (2006) 108 (11): 3541.

https://doi.org/10.1182/blood.V108.11.3541.3541

Published: 2006

Journal Articles

Bortezomib Reduces Serum Dickkopf-1 and RANKL Concentrations and Normalizes Indices of Bone Remodeling in Patients with Relapsed Multiple Myeloma.

Evangelos Terpos, Deborah Heath, Amin Rahemtulla, Kostas Zervas, Andrew Chantry, Athanasios Anagnostopoulos, Anastasia Pouli, Eirini Katodritou, Evgenia Verrou, Elisavet C. Vervessou, Meletios A. Dimopoulos, Peter Croucher

Blood (2006) 108 (11): 506.

https://doi.org/10.1182/blood.V108.11.506.506

Published: 2006

Journal Articles

Gene Modified Human Mesenchymal Stem Cells Expressing Osteoprotegerin Inhibit Osteoclast Activation and Increase Trabecular Bone Area in a Xenogeneic Murine Model of Myeloma.

Neil Rabin, MD, Chara Kyriakou, MD, Reuben Benjamin, MD, Arnold Pizzey, Orla Gallagher, BSc, Nalini Singh, Clive Buckle, PhD, Peter Croucher, PhD, Amit Nathwani, PhD, Kwee Yong, PhD

Blood (2006) 108 (11): 505.

https://doi.org/10.1182/blood.V108.11.505.505

Published: 2006

NARROW

Multiple Myeloma Progression: Dependence on Bone Marrow Adipose Tissue

Anti-Sclerostin Treatment Prevents Multiple Myeloma Induced Bone Loss and Reduces Tumor Burden

The Effect of Myeloma Cells on Bone Homeostasis Is Heterogenous and Correlates with Underlying Genetic Lesions and Bone Disease In Vivo

Targeting CDK4/CDK6 Impairs Osteoclast Progenitor Pool Expansion and Blocks Osteolytic Lesion Development in Multiple Myeloma.

In Vivo Evaluation of a BAFF Inhibitor AMG 523 Suggests Lack of Efficacy in Multiple Myeloma Tumor Models.

Myeloma bone disease and proteasome inhibition therapies

Inhibition of p38α MAPK Reduces Tumor Burden, Prevents the Development of Myeloma Bone Disease, and Increases Survival in the 5T2 and 5T33 Murine Models of Myeloma.

The Combination of Bortezomib, Melphalan, Dexamethasone and Intermittent Thalidomide (VMDT) Is an Effective Regimen for Relapsed/Refractory Myeloma and Reduces Serum Levels of Dickkopf-1, RANKL, MIP-1α and Angiogenic Cytokines.

Bortezomib Reduces Serum Dickkopf-1 and RANKL Concentrations and Normalizes Indices of Bone Remodeling in Patients with Relapsed Multiple Myeloma.

Gene Modified Human Mesenchymal Stem Cells Expressing Osteoprotegerin Inhibit Osteoclast Activation and Increase Trabecular Bone Area in a Xenogeneic Murine Model of Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only